A Retrospective Cohort Study of Infusion Reactions Due to Vectibix

Infusion Reaction Clinical Trial

Official title:
A Retrospective Cohort Study of Infusion Reactions Due to Vectibix

Status Completed

Clinical Trial Summary

The purpose of this study is to identify approximately 100 - 150 patients who have received Vectibix (Panitumumab) in offices and clinics located in Tennessee, North Carolina, South Carolina, and North Georgia from February 2004 - April 2009. Information regarding the incidence and severity of hypersensitivity infusion reactions to Vectibix (Panitumumab)will be captured. In patients who experienced hypersensitivity reactions, the following information will also be collected: premedication, treatment cycle symptoms that were experienced during chemotherapy, changes required in subsequent Vectibix (Panitumumab) or chemotherapy treatment, and outcome of the hypersensitivity reaction.

Clinical Trial Description

n/a

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

Infusion Reaction

Clinical Trial Details

NCT number	NCT01156090
Study type	Observational
Source	SCRI Development Innovations, LLC
Contact
Status	Completed
Phase	N/A
Start date	June 2010
Completion date	January 2013

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06031233` - Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie	Phase 4
Recruiting	`NCT04198623` - Efficacy of Montelukast in Reducing the Incidence and Severity of Monoclonal Antibodies Associated Infusion Reactions	Phase 2
Completed	`NCT04175834` - Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab	Phase 3